Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc.

A biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH).

Madrigal Pharmaceuticals

Madrigal (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis. For more information, visit www.madrigalpharma.com. 

Hercules Capital

Bay City Capital

Join us at Digestive Disease Week® (DDW) for an engaging Product Theater discussing a new option available for #NASH / #MASH patients with liver fibrosis. #DDW2024​

Watch how a community engages with a realistic liver model at our recent community liver health education and screening event: https://lnkd.in/g9PeyEY2

Liam Swain (recently accepted into medical school) interacts closely wth a very curious group of attendees at our Global Fatty Liver Day event.

Link to video: https://lnkd.in/g9PeyEY2

American Association for the Study of Liver Diseases (AASLD) EASL | The Home of Hepatology European Liver Patients'​ Association - ELPA LPI LIVER PATIENTS INTERNATIONAL Global Liver Institute, Canadian Association for the Study of the Liver, Prof. Shira Zelber Sagi, Jonathan G. Stine, MD MSc, FACP, Manal Abdelmalek, Rachael Sood RN, MSN, NP-C, CDCES, Arizona Liver Health, Naim Alkhouri, MD, FAASLD, Mazen Noureddin, MD, MHSc, Jörn M. Schattenberg, Zobair Younossi, Global NASH Council, Obesity Matters , Paul Brennan, Christopher Kopka, American Diabetes Association, Barcelona Institute for Global Health (ISGlobal), Jeffrey V. Lazarus, Dexcom, Michael Reiner, MBA, Elizabeth Pekas, PhD,  Donna Cryer, Madrigal Pharmaceuticals, Chris Frates, Chris Dadas

We’ll be in Orlando, FL for the American Diabetes Association's 84th Scientific Sessions. Will you? Stop by our e-poster session on #NASH / #MASH between 12:30-1:30 p.m. EDT on Sunday, June 23. Swipe to learn more. #ADA2024 ​

We are proud to sponsor Global Liver Institute's Global #FattyLiverDay, an awareness initiative that prioritizes the lives of those impacted by #NASH / #MASH. Help us increase education by joining the conversation.​

Join us in Venice, Italy for the European Association for the Study of Obesity (EASO)’s 31st European Congress on Obesity. Swipe to learn more about our #NASH / #MASH data presentations. We hope to see you there! #ECO2024

Madrigal is aware of a press release issued by the American Association for the Study of Liver Disease (AASLD) announcing the FDA approval of resmetirom.  While today is the PDUFA date for resmetirom, Madrigal has not received notification from the FDA. AASLD is removing the press release from its website.

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue							112K -	471K 320.54%	405K 14.01%	467K 15.31%	527K 12.85%
gross profit							-112K -	-471K 320.54%	-405K 14.01%	-467K 15.31%	-527K 12.85%
selling and marketing expenses
general and administrative expenses	15.70M -	15.75M 0.30%	13.39M 14.95%	9.29M 30.63%	7.67M 17.42%	15.29M 99.34%	22.65M 48.09%	21.86M 3.46%	37.32M 70.68%	48.13M 28.97%	108.15M 124.70%
selling general and administrative expenses	15.70M -	15.75M 0.30%	13.39M 14.95%	9.29M 30.63%	7.67M 17.42%	15.29M 99.34%	22.65M 48.09%	21.86M 3.46%	37.32M 70.68%	48.13M 28.97%	108.15M 124.70%
research and development expenses	71.86M -	68.20M 5.09%	54.22M 20.51%	15.93M 70.61%	24.39M 53.07%	25.39M 4.10%	72.32M 184.86%	184.81M 155.53%	205.16M 11.01%	245.44M 19.63%	271.82M 10.75%
other expenses					350K -	200K 42.86%		100K -	273K 173%
cost and expenses	87.56M -	83.95M 4.12%	67.61M 19.46%	25.22M 62.69%	32.06M 27.11%	40.68M 26.89%	94.97M 133.45%	206.67M 117.61%	242.48M 17.33%	293.57M 21.07%	380.50M 29.61%
operating expenses	87.56M -	83.95M 4.12%	67.61M 19.46%	25.22M 62.69%	32.06M 27.11%	40.68M 26.89%	94.97M 133.45%	206.67M 117.61%	242.48M 17.33%	293.57M 21.07%	379.97M 29.43%
interest expense	2.63M -	2.21M 16.07%	1.06M 51.99%	1.16M 9.71%	558K 52.06%	7.67M 1,274.73%	11.02M 43.71%			3.96M -	12.71M 220.69%
ebitda	-87.04M -	-83.28M 4.33%	-66.95M 19.61%	-25.22M 62.32%	-32.06M 27.11%	-40.68M 26.89%	-94.97M 133.45%	-206.67M 117.61%	-242.48M 17.33%	-291.39M 20.17%	-379.97M 30.40%
operating income	-87.56M -	-83.95M 4.12%	-67.61M 19.46%	-25.22M 62.69%	-32.06M 27.11%	-40.68M 26.89%	-94.97M 133.45%	-206.67M 117.61%	-242.48M 17.33%	-293.57M 21.07%	-380.50M 29.61%
depreciation and amortization	516K -	673K 30.43%	662K 1.63%	156 99.98%	77K 49,258.97%	96K 24.68%	112K 16.67%	471K 320.54%	405K 14.01%	2.19M 439.51%	527K 75.88%
total other income expenses net	-2.63M -	-2.21M 16.07%	-1.06M 51.99%	-1.16M 9.73%	350K 130.06%	200K 42.86%	11.02M 5,412%	4.43M 59.82%	636K 85.64%	-1.78M 379.72%	6.87M 485.95%
income before tax	-90.19M -	-86.16M 4.47%	-68.67M 20.30%	-26.39M 61.57%	-31.15M 18.06%	-32.81M 5.32%	-83.95M 155.85%	-202.24M 140.92%	-241.85M 19.58%	-295.35M 22.12%	-373.63M 26.50%
income tax expense				-373 -	-635K 170,141.29%	7.87M 1,339.53%	-11.14M 241.48%	-4.80M 56.90%	-768K 84%	3.96M 616.15%
net income	-90.19M -	-86.16M 4.47%	-68.67M 20.30%	-26.39M 61.57%	-31.15M 18.06%	-32.81M 5.32%	-72.81M 121.91%	-197.44M 171.17%	-241.08M 22.10%	-299.31M 24.16%	-373.63M 24.83%
weighted average shs out	2.03M -	2.81M 38.76%	171.01K 93.92%	5.20M 2,943.44%	12.24M 135.27%	14.80M 20.84%	15.39M 4.04%	15.45M 0.34%	16.54M 7.05%	17.14M 3.64%	18.69M 9.05%
weighted average shs out dil	2.03M -	2.81M 38.76%	171.01K 93.92%	5.20M 2,943.44%	12.24M 135.27%	14.80M 20.84%	15.39M 4.04%	15.45M 0.34%	16.54M 7.05%	17.14M 3.64%	18.69M 9.05%
eps	-44.48 -	-30.62 31.16%	-401.56 1,211.43%	-5.07 98.74%	-2.54 49.90%	-2.22 12.60%	-4.73 113.06%	-12.78 170.19%	-14.58 14.08%	-17.47 19.82%	-19.99 14.42%
epsdiluted	-44.48 -	-30.62 31.16%	-401.56 1,211.43%	-5.07 98.74%	-2.54 49.90%	-2.22 12.60%	-4.73 113.06%	-12.78 170.19%	-14.58 14.08%	-17.47 19.82%	-19.99 14.42%

COM:MADRIGALPHARMA

Madrigal Pharmaceuticals

Last Close

215.93

31/10 16:18

Market Cap

6.06B

Beta: -

Volume Today

663.02K

Avg: -

Preview